Latest news with #ForbesChina
Globe and Mail
14 hours ago
- Business
- Globe and Mail
Frost & Sullivan: iRegene Therapeutics Honored as "2025 Forbes China Leading Enterprises in Industry Development"
Shanghai, China--(Newsfile Corp. - June 8, 2025) - Recently, The "2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Development Selection Gala Evening of Honor," jointly organized by Frost & Sullivan and Forbes China, was successfully held at Regent Shanghai on The Bund. Amid the global trend of industrial innovation, the results of the "2025 Pioneer Innovators in Industry Development" selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. iRegene Therapeutics was honored as one of Forbes China's 2025 Leading Enterprises in Industry Development. iRegene is pioneering the future of regenerative medicine with its AI-powered, chemically induced cell therapy platform. By combining cutting-edge technology, a robust R&D ecosystem, and a globally experienced leadership team, iRegene is redefining allogeneic therapies to make them safer, more effective, and broadly accessible. This recognition highlights iRegene's continued leadership in innovation and its commitment to transforming patient care through next-generation regenerative therapies. iRegene Therapeutics Honored as 2025 Forbes China Leading Enterprises in Industry Development Aroop Zutshi, Global Managing Partner and Executive Board Director of Frost & Sullivan, and Junyi Guo, General Manager of Business Operations at Forbes China, jointly presented the 2025 Forbes China Leading Enterprises in Industry Development award. Dr. Jun Wei, Chairman of iRegene Therapeutics, was invited to attend the gala. AI-Driven Chemical-Induced Cell Therapy: Reshaping the Future of Accessible Cell Therapy Since its establishment in 2017, iRegene Therapeutics has remained committed to addressing unmet clinical needs through the development of next-generation cell therapies. With a focus on chemically induced, universal cell therapy products, iRegene aims to deliver transformative treatments for patients with currently incurable diseases. iRegene Therapeutics has a proprietary, AI-based platform for screening chemical compounds to modify specific cellular functions. The platform leverages induced pluripotent stem cells (iPSCs) to enhance treatment potential. By combining compounds to form a chemically induced culture medium, the "AI+Chem" platform can efficiently and precisely reprogram or optimize a cell's fate and function, thereby enhancing the clinical capabilities of cell therapies. With a focus on the chemical induction system, iRegene has developed a comprehensive research and development (R&D) ecosystem and an international patent system that spans the industry. This ecosystem combines the discovery of 'cell fate determinants', the screening of chemical inducers and the validation of cellular function. The system does not use viral vector construction or transgenic methods; the straightforward CMC procedure is cost-efficient. Furthermore, cell transformation and functional optimization are entirely driven by the cells' natural genetic makeup. Transformation is synchronous under chemically enhanced regulation, eliminating the risk of genetic modification. iRegene's pioneering platform has been proven through the positive outcomes of the Phase I clinical trial. In addition, iRegene's executive team has an international perspective, with all members having successful overseas experience in their specialized fields. CEO Dr Wei Jun is a leading expert in regenerative medicine and the induced pluripotent stem cell (iPSC) technology, bringing strategic leadership to the company. Chief Medical Officer Dr Cai Meng has extensive experience taking innovative therapies from discovery through clinical development, while Chief Quality Officer Ren Xiang is a senior regulatory expert who provides solid support from IND approval to NDA clearance in China, the US, and other countries. Executive Vice President Emmanuel Montet, formerly Vice President of the Asia-Pacific region at Ipsen, now leads iRegene's global business development and international strategy. To accelerate global clinical translation and commercialization, iRegene places great emphasis on the philosophy of 'cooperation and mutual benefit'. At the end of 2021, iRegene entered a long-term collaboration with Danaher Corporation to co-develop next-generation platforms for clinical application. Under this partnership, Danaher will play an active role in developing multi-directional platforms for future iRegene Therapeutics projects. This will involve supplying advanced detection instruments and technical resources relating to life sciences research, the development of effective compounds and screening, multi-omics cell mechanism research, and multi-substance screening. Danaher will help iRegene Therapeutics to enhance the efficiency of platform construction and its ability to deliver practical solutions. Danaher will also support iRegene Therapeutics in developing distinctive, innovative drug pipelines and establishing a research and production base. This strategic cooperation has recently been elevated to the iRegene - Danaher Joint Innovation Center, which is the world's first "Joint Innovation Center for Chemically Induced Therapies and Microphysiology Systems". The center will focus on integrating artificial intelligence (AI)-driven chemically induced cell therapy R&D with microphysiology systems technology. It is committed to accelerating the clinical translation and application of innovative therapies, and providing patients globally with more precise and effective treatment solutions for diseases. Danaher will fully support iRegene Therapeutics' future planning and development, aiming to jointly advance innovative development in China's life sciences research. iRegene's breakthrough technology platform, strategic advantages and dedicated team have secured continuous support from several leading venture capital firms, with cumulative financing reaching nearly 400 million RMB (55.5 million USD). The company is advancing multiple programs through clinical development, targeting a win-win situation for its products and the capital markets alike, while providing patients around the world with next-generation chemically induced cell therapies that can genuinely reverse disease progression. About iRegene Therapeutics iRegene Therapeutics is a biotechnology company committed to becoming a global leader in universal chemical-induced cell therapy. As one of the first companies to harness AI and + chemical induction for the specific functional modification of cells, iRegene offers a safer, more scalable, and cost-effective alternative to traditional gene or cell therapies. Its pipeline targets diseases with high unmet need, including neurodegenerative disorders such as Parkinson's disease and blindness. Through pioneering science, strategic global partnerships, and a visionary leadership team, iRegene is reshaping the future of regenerative medicine - making advanced therapies accessible to patients worldwide. In August 2023, the NMPA approved the commencement of Phase I clinical trials for iRegene's first product: 'Human Dopaminergic Precursor Cell, NouvNeu001'. This product was developed using the 'AI+ Chem' platform. This made it the world's first chemically induced pluripotent stem cell (iPSC)-derived therapy to enter clinical trials. In June 2024, it was approved by the U.S. FDA for overseas clinical trials. Even more groundbreakingly, in March 2024, iRegene's 'Chemical Induction Platform' became the first system ever to be granted exemption by the FDA. The company's second product, NouvNeu003, which is intended for the treatment of early-onset Parkinson's disease, received NMPA approval in December 2023 and entered Phase I clinical trials. Both NouvNeu001 and NouvNeu003 have now completed Phase I trials. The Phase I results demonstrate good safety, tolerability, and encouraging efficacy in improving motor and non-motor symptoms. The Phase II trial for NouvNeu001 began in April 2025. In parallel, iRegene's first-in-class ophthalmic therapy, was granted Orphan Drug Designation (ODD) by the U.S. FDA in March 2024.
Associated Press
14 hours ago
- Business
- Associated Press
Frost & Sullivan: iRegene Therapeutics Honored as '2025 Forbes China Leading Enterprises in Industry Development'
Recently, The '2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Development Selection Gala Evening of Honor,' jointly organized by Frost & Sullivan and Forbes China, was successfully held at Regent Shanghai on The Bund. Amid the global trend of industrial innovation, the results of the '2025 Pioneer Innovators in Industry Development' selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. iRegene Therapeutics was honored as one of Forbes China's 2025 Leading Enterprises in Industry Development. iRegene is pioneering the future of regenerative medicine with its AI-powered, chemically induced cell therapy platform. By combining cutting-edge technology, a robust R&D ecosystem, and a globally experienced leadership team, iRegene is redefining allogeneic therapies to make them safer, more effective, and broadly accessible. This recognition highlights iRegene's continued leadership in innovation and its commitment to transforming patient care through next-generation regenerative therapies. iRegene Therapeutics Honored as [2025 Forbes China Leading Enterprises in Industry Development] Aroop Zutshi, Global Managing Partner and Executive Board Director of Frost & Sullivan, and Junyi Guo, General Manager of Business Operations at Forbes China, jointly presented the 2025 Forbes China Leading Enterprises in Industry Development award. Dr. Jun Wei, Chairman of iRegene Therapeutics, was invited to attend the gala. AI-Driven Chemical-Induced Cell Therapy: Reshaping the Future of Accessible Cell Therapy Since its establishment in 2017, iRegene Therapeutics has remained committed to addressing unmet clinical needs through the development of next-generation cell therapies. With a focus on chemically induced, universal cell therapy products, iRegene aims to deliver transformative treatments for patients with currently incurable diseases. iRegene Therapeutics has a proprietary, AI-based platform for screening chemical compounds to modify specific cellular functions. The platform leverages induced pluripotent stem cells (iPSCs) to enhance treatment potential. By combining compounds to form a chemically induced culture medium, the 'AI+Chem' platform can efficiently and precisely reprogram or optimize a cell's fate and function, thereby enhancing the clinical capabilities of cell therapies. With a focus on the chemical induction system, iRegene has developed a comprehensive research and development (R&D) ecosystem and an international patent system that spans the industry. This ecosystem combines the discovery of 'cell fate determinants', the screening of chemical inducers and the validation of cellular function. The system does not use viral vector construction or transgenic methods; the straightforward CMC procedure is cost-efficient. Furthermore, cell transformation and functional optimization are entirely driven by the cells' natural genetic makeup. Transformation is synchronous under chemically enhanced regulation, eliminating the risk of genetic modification. iRegene's pioneering platform has been proven through the positive outcomes of the Phase I clinical trial. In addition, iRegene's executive team has an international perspective, with all members having successful overseas experience in their specialized fields. CEO Dr Wei Jun is a leading expert in regenerative medicine and the induced pluripotent stem cell (iPSC) technology, brings strategic leadership to the company. Chief Medical Officer Dr Cai Meng has extensive experience taking innovative therapies from discovery through clinical development, while Chief Quality Officer Ren Xiang is a senior regulatory expert who provides solid support from IND approval to NDA clearance in China, the US, and other countries. Executive Vice President Emmanuel Montet, formerly Vice President of the Asia-Pacific region at Ipsen, now leads iRegene's global business development and international strategy. To accelerate global clinical translation and commercialization, iRegene places great emphasis on the philosophy of 'cooperation and mutual benefit'. At the end of 2021, iRegene entered a long-term collaboration with Danaher Corporation to co-develop next-generation platforms for clinical application. Under this partnership, Danaher will play an active role in developing multi-directional platforms for future iRegene Therapeutics projects. This will involve supplying advanced detection instruments and technical resources relating to life sciences research, the development of effective compounds and screening, multi-omics cell mechanism research, and multi-substance screening. Danaher will help iRegene Therapeutics to enhance the efficiency of platform construction and its ability to deliver practical solutions. Danaher will also support iRegene Therapeutics in developing distinctive, innovative drug pipelines and establishing a research and production base. This strategic cooperation has recently been elevated to the iRegene – Danaher Joint Innovation Center, which is the world's first 'Joint Innovation Center for Chemically Induced Therapies and Microphysiology Systems'. The center will focus on integrating artificial intelligence (AI)-driven chemically induced cell therapy R&D with microphysiology systems technology. It is committed to accelerating the clinical translation and application of innovative therapies, and providing patients globally with more precise and effective treatment solutions for diseases. Danaher will fully support iRegene Therapeutics' future planning and development, aiming to jointly advance innovative development in China's life sciences research. iRegene's breakthrough technology platform, strategic advantages and dedicated team have secured continuous support from several leading venture capital firms, with cumulative financing reaching nearly 400 million RMB (55.5 million USD). The company is advancing multiple programs through clinical development, targeting a win-win situation for its products and the capital markets alike, while providing patients around the world with next-generation chemically induced cell therapies that can genuinely reverse disease progression. About iRegene Therapeutics iRegene Therapeutics is a biotechnology company committed to becoming a global leader in universal chemical-induced cell therapy. As one of the first companies to harness AI and + chemical induction for the specific functional modification of cells, iRegene offers a safer, more scalable, and cost-effective alternative to traditional gene or cell therapies. Its pipeline targets diseases with high unmet need, including neurodegenerative disorders such as Parkinson's disease and blindness. Through pioneering science, strategic global partnerships, and a visionary leadership team, iRegene is reshaping the future of regenerative medicine — making advanced therapies accessible to patients worldwide. In August 2023, the NMPA approved the commencement of Phase I clinical trials for iRegene's first product: 'Human Dopaminergic Precursor Cell, NouvNeu001'. This product was developed using the 'AI+ Chem' platform. This made it the world's first chemically induced pluripotent stem cell (iPSC)-derived therapy to enter clinical trials. In June 2024, it was approved by the U.S. FDA for overseas clinical trials. Even more groundbreakingly, in March 2024, iRegene's 'Chemical Induction Platform' became the first system ever to be granted exemption by the FDA. The company's second product, NouvNeu003, which is intended for the treatment of early-onset Parkinson's disease, received NMPA approval in December 2023 and entered Phase I clinical trials. Both NouvNeu001 and NouvNeu003 have now completed Phase I trials. The Phase I results demonstrate good safety, tolerability, and encouraging efficacy in improving motor and non-motor symptoms. The Phase II trial for NouvNeu001 began in April 2025. In parallel, iRegene's first-in-class ophthalmic therapy, was granted Orphan Drug Designation (ODD) by the U.S. FDA in March 2024. Media Contact Company Name: Frost & Sullivan Contact Person: Qian Li Email: Send Email Country: China Website:
Yahoo
15 hours ago
- Business
- Yahoo
Frost & Sullivan: iRegene Therapeutics Honored as "2025 Forbes China Leading Enterprises in Industry Development"
Shanghai, China--(Newsfile Corp. - June 8, 2025) - Recently, The "2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Development Selection Gala Evening of Honor," jointly organized by Frost & Sullivan and Forbes China, was successfully held at Regent Shanghai on The Bund. Amid the global trend of industrial innovation, the results of the "2025 Pioneer Innovators in Industry Development" selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. iRegene Therapeutics was honored as one of Forbes China's 2025 Leading Enterprises in Industry Development. iRegene is pioneering the future of regenerative medicine with its AI-powered, chemically induced cell therapy platform. By combining cutting-edge technology, a robust R&D ecosystem, and a globally experienced leadership team, iRegene is redefining allogeneic therapies to make them safer, more effective, and broadly accessible. This recognition highlights iRegene's continued leadership in innovation and its commitment to transforming patient care through next-generation regenerative therapies. iRegene Therapeutics Honored as 2025 Forbes China Leading Enterprises in Industry Development Aroop Zutshi, Global Managing Partner and Executive Board Director of Frost & Sullivan, and Junyi Guo, General Manager of Business Operations at Forbes China, jointly presented the 2025 Forbes China Leading Enterprises in Industry Development award. Dr. Jun Wei, Chairman of iRegene Therapeutics, was invited to attend the gala. AI-Driven Chemical-Induced Cell Therapy: Reshaping the Future of Accessible Cell Therapy Since its establishment in 2017, iRegene Therapeutics has remained committed to addressing unmet clinical needs through the development of next-generation cell therapies. With a focus on chemically induced, universal cell therapy products, iRegene aims to deliver transformative treatments for patients with currently incurable diseases. iRegene Therapeutics has a proprietary, AI-based platform for screening chemical compounds to modify specific cellular functions. The platform leverages induced pluripotent stem cells (iPSCs) to enhance treatment potential. By combining compounds to form a chemically induced culture medium, the "AI+Chem" platform can efficiently and precisely reprogram or optimize a cell's fate and function, thereby enhancing the clinical capabilities of cell therapies. With a focus on the chemical induction system, iRegene has developed a comprehensive research and development (R&D) ecosystem and an international patent system that spans the industry. This ecosystem combines the discovery of 'cell fate determinants', the screening of chemical inducers and the validation of cellular function. The system does not use viral vector construction or transgenic methods; the straightforward CMC procedure is cost-efficient. Furthermore, cell transformation and functional optimization are entirely driven by the cells' natural genetic makeup. Transformation is synchronous under chemically enhanced regulation, eliminating the risk of genetic modification. iRegene's pioneering platform has been proven through the positive outcomes of the Phase I clinical trial. In addition, iRegene's executive team has an international perspective, with all members having successful overseas experience in their specialized fields. CEO Dr Wei Jun is a leading expert in regenerative medicine and the induced pluripotent stem cell (iPSC) technology, bringing strategic leadership to the company. Chief Medical Officer Dr Cai Meng has extensive experience taking innovative therapies from discovery through clinical development, while Chief Quality Officer Ren Xiang is a senior regulatory expert who provides solid support from IND approval to NDA clearance in China, the US, and other countries. Executive Vice President Emmanuel Montet, formerly Vice President of the Asia-Pacific region at Ipsen, now leads iRegene's global business development and international strategy. To accelerate global clinical translation and commercialization, iRegene places great emphasis on the philosophy of 'cooperation and mutual benefit'. At the end of 2021, iRegene entered a long-term collaboration with Danaher Corporation to co-develop next-generation platforms for clinical application. Under this partnership, Danaher will play an active role in developing multi-directional platforms for future iRegene Therapeutics projects. This will involve supplying advanced detection instruments and technical resources relating to life sciences research, the development of effective compounds and screening, multi-omics cell mechanism research, and multi-substance screening. Danaher will help iRegene Therapeutics to enhance the efficiency of platform construction and its ability to deliver practical solutions. Danaher will also support iRegene Therapeutics in developing distinctive, innovative drug pipelines and establishing a research and production base. This strategic cooperation has recently been elevated to the iRegene - Danaher Joint Innovation Center, which is the world's first "Joint Innovation Center for Chemically Induced Therapies and Microphysiology Systems". The center will focus on integrating artificial intelligence (AI)-driven chemically induced cell therapy R&D with microphysiology systems technology. It is committed to accelerating the clinical translation and application of innovative therapies, and providing patients globally with more precise and effective treatment solutions for diseases. Danaher will fully support iRegene Therapeutics' future planning and development, aiming to jointly advance innovative development in China's life sciences research. iRegene's breakthrough technology platform, strategic advantages and dedicated team have secured continuous support from several leading venture capital firms, with cumulative financing reaching nearly 400 million RMB (55.5 million USD). The company is advancing multiple programs through clinical development, targeting a win-win situation for its products and the capital markets alike, while providing patients around the world with next-generation chemically induced cell therapies that can genuinely reverse disease progression. About iRegene Therapeutics iRegene Therapeutics is a biotechnology company committed to becoming a global leader in universal chemical-induced cell therapy. As one of the first companies to harness AI and + chemical induction for the specific functional modification of cells, iRegene offers a safer, more scalable, and cost-effective alternative to traditional gene or cell therapies. Its pipeline targets diseases with high unmet need, including neurodegenerative disorders such as Parkinson's disease and blindness. Through pioneering science, strategic global partnerships, and a visionary leadership team, iRegene is reshaping the future of regenerative medicine - making advanced therapies accessible to patients worldwide. In August 2023, the NMPA approved the commencement of Phase I clinical trials for iRegene's first product: 'Human Dopaminergic Precursor Cell, NouvNeu001'. This product was developed using the 'AI+ Chem' platform. This made it the world's first chemically induced pluripotent stem cell (iPSC)-derived therapy to enter clinical trials. In June 2024, it was approved by the U.S. FDA for overseas clinical trials. Even more groundbreakingly, in March 2024, iRegene's 'Chemical Induction Platform' became the first system ever to be granted exemption by the FDA. The company's second product, NouvNeu003, which is intended for the treatment of early-onset Parkinson's disease, received NMPA approval in December 2023 and entered Phase I clinical trials. Both NouvNeu001 and NouvNeu003 have now completed Phase I trials. The Phase I results demonstrate good safety, tolerability, and encouraging efficacy in improving motor and non-motor symptoms. The Phase II trial for NouvNeu001 began in April 2025. In parallel, iRegene's first-in-class ophthalmic therapy, was granted Orphan Drug Designation (ODD) by the U.S. FDA in March 2024. Media Contact Company Name: Frost & SullivanWebsite: PR@ To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
28-05-2025
- Business
- Yahoo
Tuya Smart Secures Prestigious Spot Among "2025 Forbes China AI Tech Enterprises Top 50"
NEW YORK, May 27, 2025 /PRNewswire/ -- Forbes China has released its "2025 Forbes China AI Tech Enterprises Top 50" list, recognizing Tuya Smart (NYSE: TUYA, HKEX: 2391), a leading global AI cloud platform service provider, as one of the country's top AI technology companies. Tuya is notably the only AI cloud platform included in this year's ranking in recognition of its robust technological capabilities and significant contributions to advancing AI accessibility and commercialization. The list highlights outstanding Chinese enterprises driving AI innovation, showcasing the industry's development and growing influence. According to Forbes China, companies that combine breakthroughs in advanced technologies with deep industry expertise are poised to shape the next technological era. This year's selection includes one primary list—Top 50 AI Tech Enterprises—alongside four subcategories. The main list focuses on identifying the most influential and representative players in China's AI sector. A panel of distinguished global and domestic AI scholars and experts evaluated nominees across several criteria, including technological innovation, market performance, and industry impact. Eva Na, Vice President of Marketing and Strategic Cooperation and CMO of Tuya Smart, said: "Being named to the '2025 Forbes China AI Tech Enterprises Top 50' is a strong endorsement of Tuya's long-term commitment to AI innovation and ecosystem development. We will continue to leverage our technological strengths and open ecosystem, working with global partners to lower barriers to AI adoption, promote equitable AI access, and deliver more user-friendly smart products that bring tangible value to businesses, households, and individuals worldwide." View original content: SOURCE Tuya Smart Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Associated Press
12-05-2025
- Business
- Associated Press
Dr. Yuxin Chen, President and CEO of Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd., Honored as a 2025 Forbes China Pioneer Innovators in Industry Development
Recently, the '2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Development Selection Gala Evening of Honor,' jointly organized by Frost & Sullivan and Forbes China, was successfully held at Regent Shanghai on the Bund. Amid the global trend of industrial innovation, the results of the '2025 Pioneer Innovators in Industry Development' selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. Dr. Yuxin Chen, with a strong academic background and solid capabilities inconvertingacademic research into industrial applications, successfully led the global R&D and clinical development of multiple first-in-class (FIC) innovative drugs. The core products of ProteLight Pharmaceuticals, founded by Dr. Chen, have entered pivotal clinical trials in both China and the United States. They demonstrate outstanding original R&D capabilities and a forward-looking international development strategy. Dr. Chen was named a 2025 Forbes China Pioneer Innovator in Industry Development. Dr. Yuxin Chen, President and CEO of Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd., [Honored as a 2025 Forbes China Pioneer Innovators in Industry Development] Dr. Wang Xin, Global Partner and President of Sullivan Greater China, together with Professor Yu Wang, Expert Advisor to the Judging Committee and Chairman of Chinese Foundation for Hepatitis Prevention and Control, presented the award to Dr. Yuxin Chen, President and CEO of Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd. China's Pioneer in Antimicrobial Peptide Innovation: ProteLight Pharma's Peceleganan Ushers in a New Era of Anti-Infective Therapy ProteLight Pharma has achieved a historic breakthrough in China's innovative drug development with its independently developed antimicrobial peptide spray Peceleganan (PL-5). It is the first antimicrobial peptide innovative drug in China to enter clinical trials and submit a New Drug Application (NDA), and it has also advanced to Phase II clinical trials in the United States. In addition, it has been granted the WHO International Nonproprietary Name (INN) 'Peceleganan,' marking the first time a Chinese-developed antimicrobial peptide compound has obtained an international nonproprietary name. Dr. Yuxin Chen, founder of ProteLight Pharma, proposed the revolutionary 'Membrane Discrimination Mechanism,' which fundamentally addresses the problem of antimicrobial resistance. In clinical trials, the Peceleganan spray demonstrated broad-spectrum efficacy, high potency, and a low potential for resistance. This breakthrough innovation received the 'Peptide Application Special Award' at the 15th Chinese International Peptide Symposium. Based on this original mechanism, ProteLight Pharma has established a world-leading rational design platform for antimicrobial peptide drug development, along with an advanced formulation R&D platform for peptide drugs, laying a solid foundation for the future growth of its product pipelines. A Full Value Chain Creator: An Outstanding Model of R&D Breakthroughs and Commercialization ProteLight Pharma has signed an exclusive cooperation agreement with China's pharmaceutical giant Chia Tai Tianqing, which is responsible for the full-scale commercialization of the PL-5 spray in the Chinese market. The company is now valued at over 2 billion RMB and has secured more than 60 million RMB in funding from the national '12th Five-Year Plan' and '13th Five-Year Plan' Major New Drug Innovation Programs, as well as from provincial and municipal science and technology funds. Notably, PL-5 has demonstrated significantly better clinical efficacy than traditional antibiotics in treating difficult-to-heal infected wounds such as diabetic foot ulcers and extensive burns. It has consistently met primary endpoints across all phases of clinical trials, providing a Chinese solution to the global problem of drug-resistant bacterial infections. In addition to anti-infective therapies, ProteLight Pharma is also expanding into oncology, autoimmune diseases, and metabolic disorders. The company has already developed several preclinical-stage innovative drug candidates in these areas. China's Strength in the Global Battle Against Antimicrobial Resistant Bacteria: Building a Sustainable Biopharmaceutical Innovation Engine Facing the growing global crisis of antibiotic resistance, ProteLight Pharma is seizing the historic opportunity for antimicrobial peptide drug development and has laid out a clear development plan. Peceleganan is expected to obtain its new drug certificate in early 2026, and the follow-up product PL-18 is scheduled to enter Phase III clinical trials in China in the fourth quarter of 2025. The company is currently advancing its Round E financing, with a focus on strengthening its R&D system and expanding its product pipeline. Dr. Yuxin Chen emphasized that ProteLight Pharma will remain committed to continuous innovation based on its original technology platform. Through further development and application of the 'Membrane Discrimination Mechanism,' the company aims to systematically address key technical challenges from drug discovery to industrialization. Committed to tackling global public health challenges, ProteLight Pharma strives to become a global leader in the field of antimicrobial peptides. This strategic positioning reflects the company's strong sense of social responsibility and highlights the ambition and strength of Chinese innovative pharmaceutical companies in global health governance. About Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd. Founded in April 2009, Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. is a high-tech biopharmaceutical company focused on the research, development, and production of peptide and small-molecule drugs. The company is based in Jiangyin Hi-Tech Industrial Development Zone, Jiangsu Province, and is recognized as a National High Tech Enterprise. ProteLight Pharma has several subsidiaries, including wholly owned R&D subsidiaries Changchun ProteLight Pharmaceutical & Biotechnology Co., Ltd. and Nanjing Denovo Pharmaceutical Technology Co., Ltd., as well as Jiangsu Putai Pharmaceutical Technology Co., Ltd., ProteLight Medical Holdings (Hong Kong) Co., Ltd., and ProteLight Pharma (Australia) Pty Ltd. Innovation-driven drug R&D and production is the core strategy of the company. It has built a diversified pipeline of first-in-class peptide and small-molecule innovative drugs, with a focus on anti-infective, oncology, autoimmune, and metabolic diseases. The company holds dozens of patents, including PCT international patents, U.S. and EU patents, Chinese invention patents, utility model patents, and design patents. Since its founding, ProteLight Pharma has undertaken over 40 scientific research projects, including the national 'Major New Drug Innovation' projects under the 12th and 13th Five-Year Plans, and the 'Funding Program for Preferential Returned Scientific Research Students Innovative and Start-ups.' The company was selected as one of the first key entrepreneurial teams by the Overseas Chinese Affairs Office and was awarded the 'Outstanding Entrepreneur Award'. Looking ahead, the company will continue to build on its antimicrobial peptide product foundation, maintaining a balanced focus on R&D and business operations. With high-quality innovative products, ProteLight Pharma aims to become a global leader in the field of antimicrobial peptide pharmaceuticals. About the 2025 Forbes China Pioneer Innovators in Industry Development Selection The '2025 Forbes China Pioneer Innovators in Industry Development' selection is jointly organized by Forbes China and Frost & Sullivan. It aims to identify and recognize entrepreneurs who demonstrate innovation and leadership in key areas such as life sciences, industry and energy, AI and information technology, and consumer finance and services. The evaluation process adopts rigorous data analysis and case study methodologies to comprehensively assess candidates' innovation strategies, market influence, and growth potential. This selection not only serves as an authoritative recognition of industry leaders, but also aims to inspire more entrepreneurs to embrace technological innovation and contribute to the sustainable development of their industries. Media Contact Company Name: Frost & Sullivan Contact Person: Qian Li Email: Send Email Country: China Website:
